Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/1727
Full metadata record
DC FieldValueLanguage
dc.contributorPeck, Kah Yongen_US
dc.contributorAndrianopoulos, Nicken_US
dc.contributorDinh, D.en_US
dc.contributorRoberts, Louiseen_US
dc.contributorDuffy, S. J.en_US
dc.contributorSebastian, M.en_US
dc.contributorClark, D.en_US
dc.contributorBrennan, A.en_US
dc.contributorOqueli, Ernestoen_US
dc.contributorAjani, A. E.en_US
dc.contributorReid, C.en_US
dc.contributorFreeman, M.en_US
dc.contributorTeh, Andrew W.en_US
dc.date.accessioned2021-07-14T03:57:31Z-
dc.date.available2021-07-14T03:57:31Z-
dc.date.issued2021-
dc.identifier.govdoc01711en_US
dc.identifier.urihttp://hdl.handle.net/11054/1727-
dc.description.abstractAims There is a paucity of evidence supporting routine beta blocker (BB) use in patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). The aim of this study was to evaluate BB use post PCI and its association with mortality. Furthermore, the study aimed to evaluate the association between BB and mortality in the subgroups of patients with left ventricular ejection fraction (LVEF) <35%, LVEF 35%–50% and LVEF >50%. Methods Using a large PCI registry, data from patients with ACS between January 2005 and June 2017 who were alive at 30 days were analysed. Those patients taking BB at 30 days were compared with those who were not taking BB. The primary outcome was all-cause mortality. The mean follow-up was 5.3±3.5 years. Results Of the 17 562 patients, 83.3% were on BB. Mortality was lower in the BB group (13.1% vs 19.5%, p=0.0001). Multivariable Cox proportional hazards model showed that BB use was associated with lower overall mortality (adjusted HR 0.87, 95% CI 0.78 to 0.97, p=0.014). In the subgroup analysis, BB use was associated with reduced mortality in LVEF <35% (adjusted HR 0.63, 95% CI 0.44 to 0.91, p=0.013), LVEF 35%–50% (adjusted HR 0.80, 95% CI 0.68 to 0.95, p=0.01), but not LVEF >50% (adjusted HR 1.03, 95% CI 0.87 to 1.21, p=0.74). Conclusion BB use remains high and is associated with reduced mortality. This reduction in mortality is primarily seen in those with reduced ejection fraction, but not in those with preserved ejection fraction.en_US
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2021-06-10T03:06:41Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2021-07-14T03:57:31Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2021-07-14T03:57:31Z (GMT). No. of bitstreams: 0 Previous issue date: 2021en
dc.titleRole of beta blockers following percutaneous coronary intervention for acute coronary syndrome.en_US
dc.typeJournal Articleen_US
dc.type.specifiedArticleen_US
dc.bibliographicCitation.titleHearten_US
dc.bibliographicCitation.volume107en_US
dc.bibliographicCitation.issue9en_US
dc.bibliographicCitation.stpage728en_US
dc.bibliographicCitation.endpage733en_US
dc.subject.healththesaurusACUTE MYOCARDIAL INFARCTIONen_US
dc.subject.healththesaurusPERCUTANEOUS CORONARY INTERVENTIONen_US
dc.identifier.doihttps://doi.org/10.1136/heartjnl-2020-316605en_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.